Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.53 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.53 |
| ▸ | MITF | O75030 | 1/20 | 0.49 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | TYR | P14679 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TAS2R38 | P59533 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7760744 | 0.82 | HDAC8 (0.60) | HDAC3HDAC11HDAC8HDAC6DEGS1 | |
| SCHEMBL8742405 | 0.82 | HDAC8 (0.53) | HDAC3HDAC11HDAC8HDAC6DEGS1 | |
| SCHEMBL19085063 | 0.80 | HDAC8 (0.58) | HDAC3HDAC11HDAC8HDAC6DEGS1 | |
| SCHEMBL23453329 | 0.78 | SMN1; SMN2 (0.69) | ALDH1A1HPGDCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL23453331 | 0.78 | SMN1; SMN2 (0.65) | ALDH1A1HPGDCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL11356835 | 0.78 | HDAC8 (0.64) | HDAC3HDAC11HDAC8HDAC6DEGS1 | |
| SCHEMBL6155615 | 0.78 | HDAC8 (0.55) | HDAC3HDAC11HDAC8HDAC6DEGS1 | |
| SCHEMBL6155618 | 0.77 | SIGMAR1 (0.54) | HDAC3HDAC11HDAC8HDAC6DEGS1 | |
| SCHEMBL3423579 | 0.77 | CYP2C9 (0.59) | HDAC3HDAC11HDAC8HDAC6ALDH1A1 | |
| SCHEMBL3423577 | 0.77 | CYP2C9 (0.59) | HDAC3HDAC11HDAC8HDAC6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1849301-A | Substituted arylthiourea derivatives useful as inhibitors of viral replication | ACHILLION PHARMACEUTICALS INC (US) | 2006-10-18 | — | — | CN | claimed |
| EP-1648862-A2 | SUBSTITUTED ARYLTHIOUREA DERIVATIVES USEFUL AS INHIBITORS OF VIRAL REPLICATION | Achillion Pharmaceuticals, Inc. (US) | 2006-04-26 | — | — | EP | claimed |
| US-20050032849-A1 | Substituted arylthiourea derivatives useful as inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. | 2005-02-10 | — | — | US | claimed |
| WO-2005007601-A2 | SUBSTITUTED ARYLTHIOUREA DERIVATIVES USEFUL AS INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | WO | claimed |
| US-7718671-B2 | Substituted arylthiourea derivatives useful as inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-7718671-B2 | Substituted arylthiourea derivatives useful as inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-7718671-B2 | Substituted arylthiourea derivatives useful as inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| CN-1849301-A | Substituted arylthiourea derivatives useful as inhibitors of viral replication | ACHILLION PHARMACEUTICALS INC (US) | 2006-10-18 | — | — | CN | disclosed |
| EP-1648862-A2 | SUBSTITUTED ARYLTHIOUREA DERIVATIVES USEFUL AS INHIBITORS OF VIRAL REPLICATION | Achillion Pharmaceuticals, Inc. (US) | 2006-04-26 | — | — | EP | disclosed |
| US-20050032849-A1 | Substituted arylthiourea derivatives useful as inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. | 2005-02-10 | — | — | US | disclosed |
| WO-2005007601-A2 | SUBSTITUTED ARYLTHIOUREA DERIVATIVES USEFUL AS INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | WO | disclosed |
| US-6562840-B1 | Non-peptidic inhibitors of proteolytic enzymes such as urokinase | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-05-13 | — | — | US | disclosed |
| EP-1150979-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2001-11-07 | — | — | EP | disclosed |
| US-20010031781-A1 | Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors | ILLIG CARL R (US) | 2001-10-18 | — | — | US | disclosed |
| US-6291514-B1 | Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-09-18 | — | — | US | disclosed |
| WO-2000047194-A9 | METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR | DIMENSIONAL PHARM INC (US) | 2001-05-31 | — | — | WO | disclosed |
| EP-1054886-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS, IN PARTICULAR AS UROKINASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-11-29 | — | — | EP | disclosed |
| WO-2000047578-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-08-17 | — | — | WO | disclosed |
| WO-2000047194-A2 | METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-08-17 | — | — | WO | disclosed |
| WO-1999040088-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS, IN PARTICULAR AS UROKINASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1999-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031781-A1 | Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors | SERPINE1, PRSS3, PRSS2 | HDAC3 893/4885HDAC11 1276/4885HDAC8 952/4885 |
| US-20050032849-A1 | Substituted arylthiourea derivatives useful as inhibitors of viral replication | TPMT, NAT1, GOT1 | HDAC3 3717/4885HDAC11 2247/4885HDAC8 2264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.